Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)

Diffuse Large B Cell Lymphoma Clinical Trial

— REMoDL-A  

Official title:

A Randomised Phase II Evaluation of Molecular Guided Therapy for Diffuse Large B-Cell Lymphoma With Acalabrutinib

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04546620
• Other study ID #: RHM CAN1500
• Status: Recruiting
• Phase: Phase 2
• Start date: October 19, 2021
• Est. completion date: July 2027

Study information

• Verified date: November 2023
• Source: University Hospital Southampton NHS Foundation Trust
• Contact: Nicole Keyworth
• Phone: 023 8120 3785
• Email: n.e.keyworth[@]soton.ac.uk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study evaluates the addition of Acalabrutinib to current standard therapy of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) for patients with previously untreated CD20 positive Diffuse Large B-cell Lymphoma (DLBCL) requiring full course chemoimmunotherapy. All patients will receive one cycle of R-CHOP. Two thirds of patients (Arm B) will go on to receive a further 5 cycles (every 21 days) of R-CHOP with Acalabrutinib. Acalabrutinib will be taken orally twice daily continuously in 21 day cycles. One third of patients (Arm A) will continue with 5 cycles of R-CHOP. Patients will be followed up initially for 24 months and then for disease status and survival until 114 progression events have been observed.

Description:

Diffuse large B-cell lymphoma (DLBCL) is the most common of the non-Hodgkin's lymphomas. Whilst the majority of patients will respond well to conventional treatment (R-CHOP - rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone), a significant number of patients lymphoma will not respond to initial therapy or their disease will return after completion of therapy. In a number of B-cell diseases an enzyme called, Bruton tyrosine kinase (BTK) prevents death of tumour cells, including in DLBCL. Acalabrutinib is an orally active BTK-inhibitor and it is thought that stopping BTK being activated may help in treating B-cell diseases. It is hypothesised that the addition of Acalabrutinib to standard R-CHOP immunochemotherapy may improve outcomes of patients with DLBCL. REMoDL-A is a randomised, phase II, open label, multicentre study that will be open in up to 50 centres. Up to 553 patients (453 randomised) will be recruited. Following informed consent all patients will receive 1 cycle of conventional R-CHOP chemotherapy. At the same time the diagnostic pathology block will be sent for molecular profiling by the Haematological Malignancy Diagnostic Service (HMDS). The delivery of the first cycle of R-CHOP will allow a sufficient interval for real time determination of molecular phenotype. Patients whose biopsies yield sufficient tumour material for profiling will be randomised 2:1 in favour of the experimental arm (R-CHOP + acalabrutinib). The primary objective will be to establish if combining acalabrutinib with R-CHOP improves efficacy, compared to R-CHOP alone, for the treatment of previously untreated patients with DLBCL to a degree that justifies further development of this approach.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 453
• Est. completion date: July 2027
• Est. primary completion date: January 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years and older

Eligibility

Inclusion Criteria:

• Histologically confirmed DLBCL, expressing CD20. Sufficient diagnostic material must be available to forward to HMDS for gene expression profiling and central pathology review. The following diagnoses by 2016 WHO classification of lymphoid neoplasms may

be included:

• DLBCL, not otherwise specified (NOS)
• T-cell/histiocyte-rich large B-cell lymphoma
• Epstein-Barr virus positive DLBCL, NOS
• ALK-positive large B-cell lymphoma
• HHV8-positive DLBCL, NOS
• High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (double-hit or triple-hit lymphoma)
• High-grade B-cell lymphoma, NOS
• At least one bi-dimensionally measurable lesion, defined as >1.5 cm in its longest dimension as measured by CT.
• Not previously treated for lymphoma and fit enough to receive combination chemoimmunotherapy with curative intent.
• Stage IAX (bulk defined as lymph node mass [either single or conglomerate] diameter >7.5cm) to stage IV disease and deemed to require a full course of chemotherapy. Patients with non-bulky IE disease will not be eligible.
• ECOG performance status 0-2 or 3 if this is directly attributable to lymphoma.
• Adequate bone marrow function with platelets > 100x109/L; neutrophils > 1.0x109/L at study entry, unless lower figures are attributable to lymphoma.
• Measured or calculated creatinine clearance > 30mls/min, (calculated using the formula of Cockcroft and Gault [(140-Age) x Mass (kg) x (1.04 (for women) or 1.23 (for men))/Serum Creatinine (µmolL)]).
• Serum bilirubin < 35µmol/L and transaminases < 1.5x upper limit of normal at time of study entry.
• Cardiac function sufficient to tolerate 300mg/m2 of doxorubicin. A pre-treatment echocardiogram or MUGA is required to establish baseline LVEF equal to or greater than institutional normal range.
• No concurrent uncontrolled medical condition.
• Life expectancy > 3 months.
• Aged 16 years or above.
• Willing and able to participate in all required evaluations and procedures in this study protocol including swallowing capsules without difficulty.
• Ability to understand the purpose and risks of the study and provide signed and dated informed consent.

Exclusion Criteria:

• Previous history of treated or untreated indolent lymphoma. However newly diagnosed patients with DLBCL who are found to also have small cell infiltration of the bone marrow or other diagnostic material (discordant lymphoma) will be eligible.
• Patients who have received immunisation with a live vaccine within four weeks prior to enrolment will be ineligible.
• Diagnosis of primary mediastinal lymphoma.
• Diagnosis of primary Central Nervous System lymphoma or secondary CNS involvement. Those patients presenting with neurological symptoms should be investigated for CNS involvement. Routine CNS imaging or diagnostic lumbar puncture will not be required in the absence of symptoms.
• History of stroke or intracranial haemorrhage in preceding 6 months.
• History of bleeding diathesis (eg, haemophilia, von Willebrand disease).
• History of drug-specific hypersensitivity or anaphylaxis to any study drug (including active product or excipient components).
• Requires or receiving anticoagulation with warfarin or equivalent antagonists (eg, phenprocoumon) within 7 days of first dose of acalabrutinib. However patients using therapeutic low molecule weight heparin or low dose aspirin will be eligible as will those receiving direct oral anticoagulants.
• Prior exposure to an inhibitor in the BCR pathway (eg, Btk inhibitors, phosphoinositide-3 kinase (PI3K), or Syk inhibitors) or BCL-2 inhibitor (eg, ABT-199).
• Requires treatment with a strong cytochrome P450 3A4 (CYP3A4) inhibitor/inducer.
• Requires treatment with proton pump inhibitors (eg, omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole). Patients receiving proton pump inhibitors should switch to short-acting H2-receptor antagonists or antacids prior to the commencement of acalabrutinib, if randomised to receive acalabrutinib.
• Active significant infection (e.g. progressive multifocal leukoencephalopathy (PML)).
• Uncontrolled autoimmune haemolytic anaemia (AIHA) or idiopathic thrombocytopenic purpura (ITP).
• Major surgery in the preceding 4 weeks of first dose of acalabrutinib (if applicable). If a subject had major surgery, they must have recovered adequately from any toxicity and/or complications from the intervention before the first dose of acalabrutinib (if applicable).
• Corticosteroid use >30 mg/day of prednisone or equivalent, for purposes other than for lymphoma symptom control. Patients receiving corticosteroid treatment with <30 mg/day of prednisone or equivalent must be documented to be on a stable dose of at least 4 weeks' duration prior to the start of Cycle 1. If glucocorticoid treatment is urgently required for lymphoma symptom control prior to the start of study treatment, prednisone 100 mg or equivalent could be given for a maximum of 14 days as a prephase. A dose of up to 30mg or prednisolone or equivalent may be used during the screening phase to control symptoms.
• Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification.
• Serological positivity for Hepatitis B, C, or known HIV infection. As per standard of care, prior to initiation of immunochemotherapy, the results of hepatitis serology should be known prior to commencement of therapy.

1. Positive test results for chronic HBV infection (defined as positive HBsAg serology) will not be eligible. Patients with occult or prior HBV infection (defined as negative HBsAg and positive total HBcAb) will not be eligible. Patients who have protective titres of hepatitis B surface antibody (HBsAb) after vaccination will be eligible.

2. Patients positive for HCV antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.

• Women who can bear children must agree to use two highly effective forms of contraception or abstinence during the study and for 12 months after the last treatment dose.
• Breastfeeding or pregnant women.
• Men who can father children must agree to use two highly effective forms of contraception with additional barrier or abstinence during the study and for 12 months after the last treatment dose.
• Men must agree to refrain from sperm donation during the study and for 12 months after the last treatment dose.
• Serious medical or psychiatric illness likely to affect participation or that may compromise the ability to give informed consent.
• Prior malignancy (other than DLBCL), except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease free for = 2 years or which will not limit survival to < 2 years.
• Has difficulty with or is unable to swallow oral medication, or has significant gastrointestinal disease, resection of the stomach or small bowel, partial or complete bowel obstruction or gastric restrictions and bariatric surgery, such as gastric bypass that would limit absorption of oral medication.
• Any immunotherapy within 4 weeks of 1st dose of the study.
• Concurrent participation in another therapeutic clinical trial.

Related Conditions & MeSH terms

• Diffuse Large B Cell Lymphoma
• Lymphoma
• Lymphoma, B-Cell
• Lymphoma, Large B-Cell, Diffuse

Intervention

Drug:
• R-CHOP
Arm A patients will receive R-CHOP alone.
• R-CHOP + acalabrutinib
Arm B patients will receive R-CHOP in combination with acalabrutinib.

Locations

Country	Name	City	State
United Kingdom	Monklands Hospital	Airdrie
United Kingdom	Victoria Hospital	Blackpool
United Kingdom	University Hospital Dorset NHS Foundation Trust (Bournemouth and Poole Hospitals)	Bournemouth
United Kingdom	Queens Hospital	Burton On Trent
United Kingdom	Addenbrooke's Hospital	Cambridge
United Kingdom	East Kent Hospitals NHS Foundation Trust	Canterbury	Kent
United Kingdom	Colchester General Hospital	Colchester	Essex
United Kingdom	Royal Derby Hospital	Derby
United Kingdom	Royal Devon and Exeter Hospital	Exeter
United Kingdom	Beatson West of Scotland Cancer Centre	Glasgow
United Kingdom	Ipswich Hospital	Ipswich
United Kingdom	St James Hospital	Leeds
United Kingdom	Leicester Royal Infirmary	Leicester
United Kingdom	Chase Farm and Barnet Hospitals	London
United Kingdom	Lewisham and Greenwich NHS Trust	London
United Kingdom	University College London Hospital	London
United Kingdom	Maidstone Hospital	Maidstone
United Kingdom	The Christie Hospital	Manchester
United Kingdom	Milton Keynes University Hospital	Milton Keynes
United Kingdom	Freeman Hospital	Newcastle
United Kingdom	Norfolk and Norwich University Hospital	Norwich
United Kingdom	Nottingham City Hospital	Nottingham
United Kingdom	Royal Oldham Hospital	Oldham
United Kingdom	Churchill Hospital	Oxford
United Kingdom	Derriford Hospital	Plymouth
United Kingdom	Queen Alexandra Hospital	Portsmouth
United Kingdom	Queen's Hospital	Romford
United Kingdom	Southampton General Hospital	Southampton
United Kingdom	Royal Stoke University Hospital	Stoke-on-Trent
United Kingdom	Singleton Hospital	Swansea
United Kingdom	Torbay Hospital	Torquay
United Kingdom	Royal Cornwall Hospital	Truro
United Kingdom	Worthing and St Richards Hospitals	Worthing

Sponsors (2)

Lead Sponsor	Collaborator
University Hospital Southampton NHS Foundation Trust	AstraZeneca

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	To explore correlation of molecular characteristics in tumour material to clinical outcomes.	Applying the following techniques to FFPE tumour material: mutational panel, FISH analysis, immunohistochemical analysis for dual protein expression of Myc and Bcl2 and dynamic changes in ctDNA and methylation based ctDNA during treatment and follow up.	At baseline, cycle 2 day 1, cycle 3 day 1, end of treatment and at 3, 6, 9 and 12 month follow-ups. Each cycle is 21 days.
Other	To explore correlation of baseline PET features including tumour burden and bone marrow involvement to clinical outcomes.	Tumour burden defined by metabolic tumour volume (MTV) and tumour lesion glycolysis (TLG). Bone marrow involvement defined by focal uptake in the bone marrow higher than liver uptake; diffuse bone marrow uptake higher than liver uptake will be recorded and correlated with bone marrow biopsy results where available (number and location of extranodal sites).	Baseline and end of treatment (up to 21 weeks).
Other	To explore combination(s) of clinical risk factors, molecular characteristics and PET features to clinical outcomes.		Baseline and end of treatment (up to 21 weeks).
Other	To compare metabolic response between molecular groups.		Baseline and end of treatment (up to 21 weeks).
Other	To update existing metabolic response criteria using advanced PET reconstructions.		Baseline and end of treatment (up to 21 weeks).
Primary	To establish if combining acalabrutinib with R-CHOP improves efficacy, compared to RCHOP alone, for the treatment of previously untreated patients with DLBCL to a degree that justifies further development of this approach.	Progression-free survival (PFS) is defined as time from registration to progression/death from any cause.	Last patient's last follow up, approximately 4.5 years. Patients who do not experience a PFS event will be censored at the date of last follow up.
Secondary	To compare PFS between molecular groups.	PFS interaction with cell of origin phenotype (ABC, GCB and unclassifiable).	Last patient's last follow-up, approximately 4.5 years.
Secondary	To compare PFS between treatment groups.	PFS interaction with clinical variables, including for example IPI, bulk, components of IPI, age and others to be determined in the SAP.	Last patient's last follow-up, approximately 4.5 years.
Secondary	To compare overall survival (OS) between both treatment and molecular groups.	Overall survival (OS), defined as time from registration to death from any cause.	Last patient's last follow-up, approximately 4.5 years. Patients who do not experience an OS event will be censored at the date of last follow-up.
Secondary	To compare event free survival (EFS) between both treatment and molecular groups.	Event-free survival (EFS), or time to treatment failure, defined as time from registration to any treatment failure including disease progression, or discontinuation of treatment for any reason.	Last patient's last follow-up, approximately 4.5 years. Patients who do not experience an EFS event will be censored at the date of last follow-up.
Secondary	To compare disease free survival (DFS) between both treatment and molecular groups.	Disease-free survival (DFS), defined as time of documentation of disease-free state to disease recurrence or death as a result of lymphoma or acute toxicity of treatment.	Last patient's last follow-up, approximately 4.5 years. Patients who do not experience a DFS event will be censored at the date of last follow-up.
Secondary	To compare time to progression (TTP) between both treatment and molecular groups.	Time to progression (TTP), defined as time from registration until documented lymphoma progression or death as a result of lymphoma. Deaths from other causes are censored at the time of death.	Last patient's last follow-up, approximately 4.5 years. Patients who do not experience a TTP event will be censored at the date of last follow-up.
Secondary	To compare duration of response (DoR) between both treatment and molecular groups.	Response duration (DoR), defined as the time from documentation of response until the documentation of relapse or progression.	Last patient's last follow-up, approximately 4.5 years. Patients who do not experience a RD event will be censored at the date of last follow-up.
Secondary	To compare overall response rate (ORR) and complete response rate (CR) between both treatment groups.	Assessment using the Lugano Response Criteria for Malignant Lymphoma.	Complete and overall response rates, as recorded at the end of treatment (up to 21 weeks) .
Secondary	To assess differences in toxicity between assigned treatments.	Evaluation of toxicity according to CTCAE version 5.	At all visits up to 24 months follow-up.
Secondary	To assess differences in quality of life between treatment arms.	Application of the EORTC QLQ-C30 and FACT-Lym questionnaires.	At baseline, cycle 2 day 1, cycle 3 day 1, cycle 5 day 1, end of treatment and at 3, 6, 12, 20 and 24 month follow-ups. Each cycle is 21 days.